Introduction
Cancer arises from the progressive evolution of a cell from normalacy through intermediate pre-malignant states to finally become invasive and metastasize (Hanahan and Weinberg, 2000) . Cells position themselves for this progression to malignancy by accumulating genetic alterations that result in the activation of oncogenes and inactivation of tumor suppressors. Studies of human mammary epithelial cells (HMEC) are beginning to provide key insight into these early genetic events to ascertain their role in fueling breast carcinogenesis (Romanov et al., 2001; Tlsty et al., 2004) .
Y-box binding protein-1 (YB-1) is a transcription/ translation factor that is overexpressed in a plethora of cancers, including human breast carcinoma (40%) (Wu et al., 2006; Habibi et al., 2008) . A pro-tumorigenic role for YB-1 is supported by its ability to directly bind Y-box promoter elements of a variety of genes, notably epidermal growth factor receptor (EGFR), ErbB2 (HER2), cyclin A and cyclin B 1 (Jurchott et al., 2003; Wu et al., 2006; Stratford et al., 2007) . Moreover, a function for YB-1 in regulating cell cycle progression is beginning to emerge through its ability to alter the expression of genes involved at the G 1 /S boundary (Basaki et al., 2010; Yu et al., 2010) . The transcriptional activity of YB-1 is dependent upon phosphorylation at its Ser-102 residue mediated by Akt/ PKB, and even more potently by p90 ribosomal S6 kinase (RSK) (Sutherland et al., 2005; Stratford et al., 2008) . To establish the importance of YB-1 in malignant transformation, transgenic mice were developed where expression was targeted to the lactating mammary gland (Bergmann et al., 2005) . The resulting mouse mammary tumors formed with 100% penetrance, and close examination revealed substantial centrosome amplification and chromosomal instability (Bergmann et al., 2005) . Given these findings, concurrent with the high prevalence of YB-1 in breast cancer, we hypothesized that it has an essential role in breast tumorigenesis.
Genomic instability, in the form of alterations to chromosome number and structure, is a characteristic feature of almost all types of cancer (Nigg, 2002; Fukasawa, 2007; Holland and Cleveland, 2009; Nigg and Raff, 2009 ). However, whether this represents a cause or consequence of tumorigenesis remains mysterious. To address this contentious issue and begin to establish a paradigm for malignant transformation, it has become imperative to study cancer during the earliest pre-malignant stages, which, to date, have remained wholly uncharacterized. A large body of evidence has recently been compiled indicating that amplification of centrosomes has the potential to cause mitotic defects that lead to chromosomal instability (Nigg, 2006; Basto et al., 2008; Ganem et al., 2009) . According to this model, centrosome abnormalities would need to emerge early during neoplastic progression. Ultimately, through Darwinian selection, a karyotype adept at enhancing tumor progression would materialize and expand (Fujiwara et al., 2005; Shi and King, 2005) . Of all sporadic breast cancer, 20-30% exhibit amplification of HER2, prompting us to address if this is a common feature of pre-malignancy that arises through targeted genomic instability preceding clonal outgrowth (Slamon et al., 1987) .
In this study, we examined the role of YB-1 during pre-malignancy to uncover the molecular events that define the earliest transitions in breast cancer initiation and progression. A comprehensive understanding of these processes will usher the development of novel therapeutics that target the process, rather than the consequences, of tumorigenesis.
Results

YB-1 alters the expression and activity of cell cycle-associated proteins
To address the potential contribution of YB-1 in the initiation of tumorigenesis, we engineered non-malignant H16N2 HMECs that conditionally expressed the gene under control of a tetracycline-inducible promoter (designated HTRY cells). HMECs containing an inducible LacZ construct served as a matched control (designated HTRZ cells). The ectopic expression level of YB-1 achieved in this model closely recapitulated that observed in established cancer cell lines (Supplementary Figure S1A) . Further characterization revealed that both cell lines were karyotypically normal (data shown below) and possessed similar telomerase activity deeming them genetically stable, and thus amenable for investigating early transformation (Supplementary Figure S1B) .
To gain a global understanding into proteome remodeling following YB-1 induction, we utilized the Kinex antibody microarray platform (Kinexus Bioinformatics Corporation, Vancouver, Canada), which allowed us to probe the expression and activation status (levels of phosphorylation) of over 600 proteins concurrently. From this unbiased protein array, we identified 56 proteins with altered expression (Supplementary  Table S1 ) many of which are fundamental in regulating centrosome dynamics and the cell cycle (Table 1) . Identification of known YB-1 transcriptional targets, including HER2, strongly supported the fidelity of the screen. We prioritized subsequent analysis on the active LIM kinases (pLIMK1/2 T508/T505 ), as they exhibited the most profound increase in level (365%) following YB-1 induction. This correlation was validated both by immunoblotting ( Figure 1a ) and immunofluorescence staining (Figure 1b) . In a reciprocal experiment, silencing YB-1 with small interfering RNA (siRNA) in MDA-MB-231 and SUM149 breast cancer cell lines repressed the phosphorylation of LIMK1/2 at Thr-508/ Thr-505, with minimal effect on total LIMK1 expression ( Figure 1c ). To confirm these results, we utilized a complimentary pharmacological approach for suppression of YB-1 activity using a signal transduction inhibitor to RSK. Our prior work indicated that inhibition of RSK directly impaired YB-1 phosphorylation and activity (Stratford et al., 2008) . Treating MDA-MB-231 cells with the RSK inhibitor BI-D1870 (a gift from Ching-Shih Chen, The Ohio State University, Columbus, OH, USA) yielded complete suppression of pLIMK1/2 T508/T505 , highlighting that pYB-1 S102 was necessary to promote LIMK1/2 activation ( Figure 1d ). These data were mirrored using siRNA against RSK1 and RSK2 (Supplementary Figure S2) . Previous reports implicated LIMK1/2 as centrosomal proteins (Sumi et al., 2006; Chakrabarti et al., 2007) and, accordingly, we wanted to examine the localization in our HTRY cell model. At 96-h post-YB-1 induction, we observed punctate pLIMK1/2 T508/T505 staining that corresponded to the centrosome as demonstrated by co-localization with the centrosomal marker g-tubulin (Figure 1e ).
Cytokinesis failure primes cells for pre-malignant transformation With YB-1 regulating a myriad of cell cycle-associated genes, we wondered how cells from a non-malignant background would respond to expression of the gene. One of the earliest and most remarkable changes in the HTRY cells following YB-1 induction was the strikingly high incidence of multinucleated cells (Figure 2a) . At 48 h following YB-1 induction, which corresponded roughly to the doubling time of these cells (data not shown), 28% of HTRY cells were binucleate thus (Figure 2b ). Previous work has demonstrated that LIMK1 localizes to the cleavage furrow during cytokinesis (Sumi et al., 2006) , and its overexpression is associated with polyploidy (Amano et al., 2002) . Based on its role in modulating actin dynamics (Bernard, 2007) , a likely explanation for the defect in cytokinesis might, therefore, be that deregulation of LIMK1/2 perturbs the stability of the contractile ring. In cytokinetic HTRZ cells, pLIMK1/2 T508/T505 was concentrated in the junction between the two daughter cells as observed by immunofluorescence. Accordingly, F-actin was visualized, using phalloidin, along the cleavage furrow and at the nuclear periphery (Figure 2c ). On the other hand, in cytokinetic HTRY cells, pLIMK1/2 T508/T505 was strongly expressed but remained diffused throughout the cytoplasm (Figure 2c) . Consequently, the actin cytoskeleton failed to reposition itself for cytokinesis. Another well-established protein at the cleavage furrow, polo-like kinase 1 (PLK1), correctly localized in HTRY cells during telophase; however, the actomyosin contractile ring consistently failed to form in these cells (Supplementary Figure S3) . This was in contrast to HTRZ cells, which formed a tight contractile ring with PLK1 characteristically localized to the midzone between the dividing cells. This supports our hypothesis that YB-1 promotes cytokinesis failure through deregulation and subsequent mislocalization of LIMK1/2.
Cell cycle checkpoint slippage potentiates centrosome amplification leading to aneuploidy Cytokinesis failure can lead to both centrosome amplification and production of tetraploid cells, which could set the stage for the development of tumor cells (Fujiwara et al., 2005) . We examined whether YB-1 expression allowed for cells arrested in cytokinesis to slip through cell cycle checkpoints and re-enter mitosis with multiple centrosomes and a compromised genome. At 96-h post-YB-1 induction, HTRY cells demonstrated centrosome amplification leading to multipolar spindle formation in mitosis (Figure 3a) . Consequently, kinetochore bi-orientation was not established resulting in failed segregation, which manifested as lagging chromosomes at the metaphase plate and micronuclei (Figure 3a) . Quantifying the proportion of tetraploid cells (44N DNA content) and those with YB-1 is a cancer susceptibility gene AH Davies et al supernumerary centrosomes (42 centrosomes) revealed a significant increase of 4.5-fold and 12.2-fold, respectively, between the HTRY and HTRZ cells (Figure 3b ). Deeper interrogation uncovered that the amplified centrosomes contained an excess of mother, but not daughter, centrioles (Supplementary Figure S4A) . Specifically, the 1:1 mother:daughter centriole ratio observed in the HTRZ cells approached 3:1 in the HTRY cells (Supplementary Figure S4B) . Having established the importance of pYB-1 S102 at the centrosome, it is not surprising that the described phenotype was contingent upon YB-1 Ser-102 phosphorylation, as transient expression of YB-1 S102D in HTRZ cells could recapitulate the phenotype, whereas YB-1 S102A could not (Supplementary Figure S5A) . Moreover, the incidence of aneuploidy and centrosome amplification was most profound in YB-1 S102D -overexpressing MDA-MB-231 cells by a significant margin (Supplementary Figure S5B) .
Due to HPV-16 E6/E7 immortalization, the p53 and retinoblastoma (Rb) tumor suppressor genes are inactivated in the HTRZ and HTRY cells. To ascertain if this background was necessary to generate the abnormal phenotypes observed in HTRY cells, we transfected YB-1 into the 184-hTERT cell line. The parental cells, which express no YB-1, have been extensively characterized to be chromosomally stable with a nearly normal karyotype (Raouf et al., 2005) . Transient expression of YB-1 for 96 h was sufficient to promote polyploidy and centrosome amplification ( Figure 3c ). We also observed early indicators of genomic instability, including lagging chromosomes and micronuclei ( Figure 3c ). The faithful recapitulation of phenotypes observed between the HTRY and 184-hTERT-YB-1 cells indicates that YB-1 expression alone is sufficient to drive genomic instability without the requirement for p53 and Rb deregulation.
One would expect that given the centrosome amplification coupled with aneuploid DNA content that the YB-1 induced cells would be subject to cell cycle arrest. To our surprise, only 18% of HTRY cells were classified as being in the G 1 -phase of the cell cycle based on DNA content. This was in stark contrast to 66% of HTRZ cells (Figure 3d ), strongly supporting the notion that HTRY cells resist anti-proliferative signals and slip through the G 1 /S checkpoint. Consistent with our findings of a cytokinesis defect, 62% of HTRY cells were in G 2 /M-phase compared with 14% of HTRZ cells Figure 2 Pre-malignancy was initiated by pLIMK1/2 T508/T505 mislocalization leading to cytokinesis failure. (a) HTRZ and HTRY cells were induced with doxycycline for 48 h, and immunostained with a-tubulin antibody (green) to define cell boundaries. Visually, many HTRY cells were binucleate (arrows) and, thus, (b) we quantified the proportion of HTRZ and HTRY cells displaying this phenotype. In all, 200 cells were assessed in three independent experiments (**Po0.01). (c) Immunofluorescence staining was employed to evaluate the spatial localization of pLIMK1/2 T508/T505 (red) and phalloidin (green) in cytokinetic HTRZ and HTRY cells following a 48-h induction with doxycycline. pLIMK1/2 T508/T505 was concentrated in the cleavage furrow of HTRZ cells promoting stabilization of the actomyosin contractile ring (arrow). In HTRY cells, pLIMK1/2 T508/T505 remained diffused throughout the cytoplasm, and the contractile ring failed to form (arrow).
YB-1 is a cancer susceptibility gene AH Davies et al ( Figure 3d ). To differentiate between cells arrested at the G 2 checkpoint and those that have progressed into M-phase, we quantified pHistone H3 S10 by immunofluorescence. In agreement with increased DNA content, 23% of HTRY cells were positive for pHistone H3 S10 , thus truly in mitosis, compared with 3% of HTRZ cells (Figure 3e ). This implies that overcoming the cytokinesis defect maybe a rate-limiting step in tumorigenesis.
We next assessed changes in signal transduction to define a mechanism to explain the observed slippage through the G 1 /S checkpoint. Following 96 h of YB-1 induction, strong expression of HER2 was detected correlative with RSK activation. Accordingly, p27 Kip1 , an inhibitory target of RSK and negative regulator of cyclin E/CDK2, was suppressed (Figure 3f ). These data demonstrate that YB-1 deregulates the cell cycle by altering signal transduction to favor a proliferative program.
Identification of YB-1 as a centrosomal protein The data described above establish the importance of YB-1 in regulating centrosomal proteins, with a role in promoting amplification of the organelle during premalignancy. On this basis, we next explored whether YB-1 was itself directly associated with the centrosome. Co-localization between pYB-1 S102 and pericentrin, a Kip1 pathway, thereby promoting cyclin E/CDK2 overexpression.
YB-1 is a cancer susceptibility gene AH Davies et al centrosomal marker, was observed in both interphase and mitotic HTRY cells using immunofluorescence (Figure 4a) . Notably, during metaphase, pYB-1 S102 was expressed along the entire length of the mitotic spindle. In MDA-MB-231 cells, pYB-1 S102 was found to co-localize with pericentrin confirming its association with centrosomes was not unique to our inducible system, but rather extended to established cancer cell lines (Supplementary Figure S6A) . To validate YB-1 as a bona fide centrosomal protein, we mapped both FLAG:YB-1 (Supplementary Figure S6B) and GFP: YB-1 (Supplementary Figure S6C) to the centrosome using antibody directed against the FLAG epitope and direct immunofluorescence, respectively.
To ascertain whether phosphorylation was a prerequisite for YB-1 centrosomal localization, we generated MDA-MB-231 cells stably expressing FLAG: YB-1 WT , FLAG:YB-1 S102D and FLAG:YB-1 S102A protein (Figure 4b ). Double immunofluorescence using anti-FLAG and anti-pericentrin antibodies revealed that the centrosomal localization of YB-1 was contingent upon phosphorylation of the Ser-102 residue. FLAG: YB-1 S102D protein, which mimicked constitutively phosphorylated YB-1, was detected in 93.5% of centrosomes. In contrast, the non-phosphorylatable FLAG: YB-1 S102A protein failed to localize to the centrosomes (Figures 4c and d) . Collectively, these data provide insight into the dependence on phosphorylation for the trafficking, retention and/or function of YB-1 at the centrosome.
To functionally examine the role of YB-1 at the centrosome, we began by performing co-immunoprecipitation experiments, which revealed physical association between FLAG:YB-1 and the centrosomal proteins, pericentrin and g-tubulin (Figure 5a ). We further queried whether LIMK1 was part of a YB-1 centrosomal complex; however, the two proteins failed to co-precipitate (data not shown). Next, we silenced YB-1 in MDA-MB-231 cells using two independent siRNA sequences (siYB-1#1 and siYB-1#2), which in turn, was found to yield substantial enlargement and morphological changes of the centrosomes as visualized by immunofluorescence targeting pericentrin (Figure 5b ). Further investigation uncovered that these centrosomes harbored large clusters of g-tubulin ring complexes (Figure 5b ). We quantified a 3.3-4.1-fold increase in centrosome area at 96-h post-siYB-1 transfection relative to mock-transfected cells (Figure 5c ). Importantly, because Ser-102 phosphorylation was a necessity for YB-1 to localize at the centrosome, we wanted to assess if the mere inhibition of protein activity would be sufficient to alter centrosome structure. In agreement with the YB-1 siRNA experiments, treating cells with 1 or 10 mM BI-D1870 for 24 h prompted the emergence of cells containing enlarged centrosomes with numerous g-tubulin ring complexes (Supplementary Figure S7A) . Figure 4 pYB-1 S102 localized to the centrosomes throughout the cell cycle. (a) Immunofluorescence staining with antibodies against pYB-1 S102 (green) and pericentrin (red) demonstrated that pYB-1 S102 was localized to the centrosomes in both interphase and mitotic HTRY cells (arrows). pYB-1 S102 was predominately nuclear; however, it dissociated from DNA at metaphase and extended along the length of the mitotic spindle. (b) To evaluate the importance of YB-1 Ser-102 phosphorylation for its centrosomal localization, we generated MDA-MB-231 cells stably expressing FLAG:YB-1 WT , FLAG:YB-1 S102D and FLAG:YB-1 S102A protein. Immunoblotting confirmed ectopic expression of the tagged-proteins. (c, d) Quantification of FLAG (green) and pericentrin (red) co-localization in 250 interphase cells revealed that FLAG:YB-1 WT and FLAG:YB-1 S102D proteins, but not FLAG:YB-1 S102A protein, localized to the centrosomes (arrows). Data represents a compilation from three independent experiments (***Po0.001).
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Specifically, the centrosomes increased in area by up to 2.9-fold relative to the dimethyl sulfoxide (DMSO)-treated controls (Supplementary Figure S7B) . In further support, we observed increased centrosomal area in MDA-MB-231 cells stably expressing YB-1 S102A mutant protein (Supplementary Figure S7C ). Finally, to analyze if the changes to centrosome structure correlated with altered function, we performed microtubule-regrowth assays to detect defects in centrosome-mediated microtubule nucleation and anchoring. The assay was used to assess a fundamental parameter of centrosome function, that is, the ability to regrow microtubules following depolymerization. Displacement of YB-1 from the centrosome following siRNA silencing clearly delayed microtubule-regrowth, as asters of short microtubules only began to emerge after a 5 min regrowth as opposed to 1 min in mock-transfected cells (Figure 5d ). This clearly demonstrates that loss of YB-1 perturbs normal centrosome function. Taken together, these results provide strong evidence for a previously uncharacterized, yet essential, role for YB-1 at the centrosome.
Genomic instability arises during pre-malignancy to generate clones with strong tumorigenic potential To better understand the aneuploidy and chromosomal instability that emerge as a consequence of centrosome amplification during pre-malignancy, we assessed metaphase chromosomes. The majority of uninduced HTRZ and HTRY cells, as well as induced HTRZ cells, had a normal diploid karyotype. A small subset was classified as 'near diploid' (40-52 chromosomes; Figure 6a ). In stark contrast, 94% of induced HTRY cells were aneuploid (Figure 6a ). Further to these numerical abnormalities, structural chromosome aberrations were readily detected in the induced HTRY cells. Dramatic increases of X5.5-fold in the appearance of dicentric chromosomes and double minutes were observed in the HTRY spreads compared with those from HTRZ cells. Most strikingly, there was a 17.6-fold increase in acentric pairs and 13.2-fold increase in acentric fragments between HTRY and HTRZ spreads, indicating that YB-1 promoted extensive chromosome breakage (Figure 6b ). In addition, defective sister chromatid cohesion was detected in the HTRY cells. Almost half of these cells exhibited a lack of primary constriction, identified by primary constriction gaps (PCGs) between sister chromatids at metaphase, compared with 11% of HTRZ cells (Supplementary Figure S8) .
To address whether genomic instability initiated by YB-1 could promote an optimal karyotypic composition for tumorigenesis, the frequency of HER2 amplification was measured using fluorescence in situ hybridization. 
We uncovered that 11% of HTRY cells were positive for HER2 amplification (HER2:CEP17 42.2). No HTRZ cells exhibited HER2 amplification (Figure 6c ). Upon a more rigorous assessment, we noted that 20% of the HTRY cell population contained low-level HER2 amplification (HER2:CEP17 between 1.5 and 2.2; Figure 6c ). The HER2 amplification in HTRY cells was largely undetected until they reached tetraploid DNA content. At this time there was an apparent relaxation in the mechanisms safeguarding genomic stability, and the number of HER2 signals began to exceed the number of centromeres, a hallmark of gene amplification (Supplementary Figure S9A and S9B). Collectively, these data indicate that a subset of pre-malignant cells have an amplification at the HER2 locus that could enhance their tumorigenic potential.
We conclude from our data that YB-1 is instrumental in activating a tumorigenic program that manifests as a cytokinesis defect, and progresses toward the emergence of HER2-positive cancer (Figure 7 ). From this, we have proposed a model of pre-malignant progression.
Discussion
In the present study, we propose a distinctive model of breast cancer pre-malignancy whereby YB-1 enables the YB-1 is a cancer susceptibility gene AH Davies et al evolution of HMECs toward a tumorigenic fate. A cytokinesis defect acted as the initial trigger for transformation promoting centrosome amplification and aneuploidy, which were potentiated by cell cycle checkpoint slippage. In turn, we identified a small population of cells harboring amplification at the HER2 locus. These studies provide significant insight into the process of tumor initiation, and demonstrate how YB-1 alone can initiate a program that primes cells for tumorigenesis.
Although YB-1 upregulation is well characterized in breast cancer cell lines and advanced stage primary tumors (Janz et al., 2002; Kohno et al., 2003; Habibi et al., 2008; To et al., 2010) , a role for the gene in tumor initiation and pre-malignant progression is unknown. Chromosomal aberrations observed in YB-1 transgenic mice prompted us to address if ectopic YB-1 expression in genetically stable HMECs acted to directly destabilize the genome as a prelude to malignancy (Bergmann et al., 2005) . In this study, we have demonstrated that expression of the gene promoted gross alterations to the centrosomal milieu and, ultimately, led to centrosome amplification. Most notably, a strong activation of LIMK1/2 was detected at the centrosomes. Likewise, in prostate cancer LIMK is expressed at the centrosome and has been linked to chromosomal instability and metastasis (Yoshioka et al., 2003; Chakrabarti et al., 2007; Davila et al., 2007) . An important finding of this study was that cytokinesis failure is the predominant mechanism for the amplification of centrosomes during pre-malignancy. We identified that sustained upregulation and mislocalization of active LIMK1/2 by YB-1 was sufficient to induce a cytokinesis defect. This could be attributed to enhanced actin polymerization at the cleavage furrow (Yang et al., 2004) . Given these results, we propose that YB-1 causes early changes in cytokinesis and centrosomal architecture that lead to eventual chromosomal instability.
In this work, we have established YB-1 as a centrosomal protein. This was found to be contingent upon phosphorylation of the Ser-102 residue in the cold shock domain, implying that this domain is minimally required for centrosomal trafficking. Especially interesting is the fact that the cold shock domain is necessary for binding oligonucleotides, including RNA due to the presence of two RNP motifs (Bouvet et al., 1995) . As the centrosome contains an intrinsic compliment of RNA (Alliegro et al., 2006) , it is possible that YB-1 is involved in regulating their translation. YB-1 has already been shown to induce cap-dependent translation of RNA giving credence to this hypothesis (Evdokimova et al., 2009) . A second function for YB-1 at the centrosome may be to mediate protein stability via physical association. It has been demonstrated that YB-1 interacts with a myriad of proteins, including PCNA, MSH2 and DNA polymerase d, via B/A repeats residing in the C-terminal domain (Ise et al., 1999; Gaudreault et al., 2004) . It is tempting to speculate that centrosomal proteins may represent an underappreciated pool with strong capacity to promote tumorigenesis, by their inherent ability to directly interface with the genome. In support of this, deregulation of centrosomal proteins including Aurora A, BRCA1 and PLK1 all promote genomic instability with eventual cellular transformation (Scully, 2000; Takai et al., 2005; Wang et al., 2006) .
Studies of HMECs have proven effective in providing key insights into the early genetic events that fuel breast carcinogenesis (Elenbaas et al., 2001; Romanov et al., 2001; Tlsty et al., 2004; Dimri et al., 2005; Dumont et al., 2009) . In this study, we report that YB-1 expression in this model leads to catastrophic genetic changes, which if left unchecked could allow for the replication of cells containing vast chromosomal amplifications and rearrangements. Because YB-1-expressing HTRY cells fail to arrest following genomic destabilization, it suggests that mutant cells are able to escape the necessary checkpoints needed to eliminate such renegade cells. Permissiveness through the cell cycle could relate to direct YB-1 transcriptional targets, such as CCNB1, CDC6, PCNA, and TOPO2 (Shibao et al., 1999; Jurchott et al., 2003; Basaki et al., 2010; Yu et al., 2010) . We chose to address the possibility that YB-1 permits the expansion of cells harboring specific amplifications common to breast cancer. Notably, we describe HER2 as being amplified in a small subset of HTRY cells. We speculate that over time this population of cells would clonally expand due to the distinct survival advantage brought about by HER2 overexpression. Moreover, this study furthers our understanding of the relationship between YB-1 and HER2 as previously described by our laboratory (Wu et al., 2006; Lee et al., 2008; Dhillon et al., 2010) . Our previous studies show that YB-1 directly binds to the HER2 promoter in cells where the gene is known to be amplified (Wu et al., 2006) . One could envisage that YB-1 is permissive for allowing cells with HER2 amplification to slip through the cell cycle checkpoints. Following this, YB-1 is poised to increase the expression of HER2 by binding directly to its promoter. This too may explain why YB-1 is highly expressed in B65% of HER2-positive breast tumors (Habibi et al., 2008) . Future work will focus on identifying additional genomic rearrangements that frequently materialize during pre-malignancy.
We report that increased expression of YB-1 is a single event sufficient to uncouple genomic integrity and cell cycle progression during breast cancer pre-malignancy. In summary, our findings argue that YB-1 has a principal role in the early evolution of cancer, and thus represents a promising biomarker and therapeutic target.
Materials and methods
Cell culture and drug treatments H16N2 HMEC with tetracycline-inducible YB-1 (HTRY) or LacZ (HTRZ) were generated using the T-Rex system (Invitrogen, Burlington, ON, Canada), as previously described (Band et al., 1990; Berquin et al., 2005) . The cells were cultured in Ham's F12 media, and induction was achieved through the addition of 1 mg/ml doxycycline (Calbiochem, Gibbstown, NJ, USA). The human mammary epithelial 184-hTERT cell line (a gift from Dr J. Carl Barrett, National Institutes of Health, Bethesda, MD, USA) was cultured in supplemented HuMEC media (Invitrogen). LCC6, MDA-MB-231 (American Tissue culture collection, Manassas, VA, USA) and SUM149 (Asterand, Detroit, MI, USA) breast cancer cell lines were cultured as recommended.
For treatment with BI-D1870, MDA-MB-231 cells were seeded at a density of 3 Â 10 5 cells in a six-well plate. Subsequently, cells were treated with a DMSO vehicle or BI-D1870 (1 or 10 mM) for 24 h.
Kinexus Kinex antibody mircoarray HTRY cells were induced for 96 h. Comparisons were made to cells not treated with doxycycline. Protein was sent to Kinexus Bioinformatics Corporation (Vancouver, BC, Canada) for hybridization and analysis using the Kinex KAM-1.1 antibody microarray.
Immunoblotting, immunoprecipitation and immunofluorescence
Immunoblotting, immunoprecipitation and immunofluorescence were performed as described previously (Wu et al., 2006; Stratford et al., 2008; Finkbeiner et al., 2009) . The origin and dilutions of all antibodies used in this study are detailed in Supplementary Table S2 . For immunoprecipitation, 500 mg of cell lysate was pre-cleared with 35 ml of protein G agarose (Sigma, St Louis, MO, USA) before overnight antibody incubation. The proteins were retrieved through the addition of protein G agarose for 2 h and eluted in 5 Â SDS-sampleloading buffer heated to 100 1C for 5 min. For immunofluorescence staining, antibodies were diluted in ICC buffer (10% bovine serum albumin, 2% goat serum and 1% saponin in phosphate-buffered saline), and all incubations were carried out at room temperature for 1 h with three washes in phosphatebuffered saline following each of the incubations. Cells were mounted using ProLong Gold antifade reagent containing DAPI (Invitrogen). Images were acquired using an Olympus FV1000 laser scanning confocal microscope (Olympus, Center Valley, PA, USA), a DeltaVision personalDV live cell imaging microscope (Applied Precision, Issaquah, WA, USA) or an Olympus BX61 epifluorescence microscope, and analyzed with ImageJ 1.43 (National Institutes of Health, Bethesda, MD, USA).
siRNA and plasmid transfections Cells were transfected with 20 nM of siRNA to RSK1, RSK2, YB-1 or scrambled control using Lipofectamine RNAiMAX (Invitrogen). The siRNA target sequences are provided in Supplementary Table S3 . The empty vector, YB-1 WT , YB-1 S102A and YB-1 S102D constructs have previously been described (Sutherland et al., 2005; Wu et al., 2006; Finkbeiner et al., 2009) . Plasmid transfections were performed using 4 mg of DNA and carried out with Lipofectamine 2000 (Invitrogen). Stable transfectants were generated and selected in G418 (400 mg/ml; Invitrogen). The GFP:YB-1 construct (Guay et al., 2006) was transfected into MDA-MB-231 cells by electroporation with Amaxa Nucleofactor Kit V, using the manufacturer's recommendations (Lonza, Walkersville, MD, USA).
Microtubule regrowth assay
SiRNA-transfected MDA-MB-231 cells were treated with 5 mM nocodazole for 1 h to depolymerize all microtubules. Nocodazole was then removed by washing twice with Dulbecco's modified Eagle's medium. At 1, 5 and 10 min after regrowth, the cells were fixed with 100% methanol and stained with a-tubulin and g-tubulin antibodies.
Cell cycle analysis HTRZ and HTRY cells were seeded in 96-well plates and induced for 96 h. The cells were subsequently fixed using 2% paraformaldehyde and stained with Hoechst 33 342 (1 ug/ml; Sigma) for 30 min. Based on total nuclear Hoechst intensity, the proportion of cells in each stage of the cell cycle was analyzed by Cell Cycle Bioapplication software on a high content screening instrument (ArrayScan VTI, Thermo Fisher Scientific, Yokohama, Japan).
Chromosome spreads
Following a 96-h induction, HTRZ and HTRY cells were treated with 0.1 mg/ml colcemid (Invitrogen) for 2 h. Mitotic chromosomes were resuspended in hypotonic solution (75 mM KCl) for 20 min and fixed using methanol:glacial acetic acid (3:1), as previously described (Barber et al., 2008) . Metaphase chromosomes were imaged using a Zeiss Axioplan digital imaging microscope and analyzed with Metamorph imaging software (Universal Imaging Corp., Downingtown, PA, USA). For analysis, we assessed chromosomal abnormalities based on their incidence with 'mild' referring to less than 5 occurrences in a spread, 'moderate' between 5 and 20, and 'severe' greater than 20. PCGs were defined as a clear separation between DAPI-stained sister chromatids. The severity ranged from only 1 or 2 chromosomes in a spread exhibiting a gap (PCG I ), to between 3 and 10 chromosomes (PCG II ), to no semblance of cohesion (PCG III ).
HER2 fluorescence in situ hybridization
Asynchronous HTRZ and HTRY cells were prepared for chromosome analysis as described above. Interphase cells were hybridized with LSI HER2 and CEP17 probe using the PathVysion HER2 DNA Probe Kit at the Center for Translational and Applied Genomics (Vancouver, BC, Canada). Analysis of fluorescence in situ hybridization signals was performed in 100 randomly selected cells. HER2 amplification was defined as a HER2:CEP17 ratio of greater than 2.2. A HER2:CEP17 ratio o1.5 was considered negative for HER2 amplification, whereas a ratio near the cut-off (1.5-2.2) was interpreted as intermediate amplification.
Telomerase assay
The telomerase activity in 1 mg of cell lysate from HTRZ and HTRY cells was measured using the Quantitative Telomerase Detection Kit (Allied Biotech, Vallejo, CA, USA), following the manufacturer's instructions. Each sample was analyzed in triplicate. A no template control and cell lysate from telomerase-positive cells (MDA-MB-231) were included in each experiment.
Statistical analysis
Data from at least three independent experiments are reported as mean ± standard deviation. Significance was examined using a paired Student's t-test, where *Po0.05, **Po0.01 and ***Po0.001.
